<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:22:53Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6445481" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6445481</identifier>
        <datestamp>2019-04-17</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Diabetologia</journal-id>
              <journal-id journal-id-type="iso-abbrev">Diabetologia</journal-id>
              <journal-title-group>
                <journal-title>Diabetologia</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0012-186X</issn>
              <issn pub-type="epub">1432-0428</issn>
              <publisher>
                <publisher-name>Springer Berlin Heidelberg</publisher-name>
                <publisher-loc>Berlin/Heidelberg</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6445481</article-id>
              <article-id pub-id-type="pmcid">PMC6445481</article-id>
              <article-id pub-id-type="pmc-uid">6445481</article-id>
              <article-id pub-id-type="pmid">29728717</article-id>
              <article-id pub-id-type="pmid">29728717</article-id>
              <article-id pub-id-type="publisher-id">4619</article-id>
              <article-id pub-id-type="doi">10.1007/s00125-018-4619-x</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Welsh</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <address>
                    <email>Paul.Welsh@glasgow.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rankin</surname>
                    <given-names>Naomi</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Li</surname>
                    <given-names>Qiang</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mark</surname>
                    <given-names>Patrick B.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>WÃ¼rtz</surname>
                    <given-names>Peter</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ala-Korpela</surname>
                    <given-names>Mika</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marre</surname>
                    <given-names>Michel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Poulter</surname>
                    <given-names>Neil</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamet</surname>
                    <given-names>Pavel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                  <xref ref-type="aff" rid="Aff16">16</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chalmers</surname>
                    <given-names>John</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Woodward</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff17">17</xref>
                  <xref ref-type="aff" rid="Aff18">18</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sattar</surname>
                    <given-names>Naveed</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2193 314X</institution-id><institution-id institution-id-type="GRID">grid.8756.c</institution-id><institution>BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular &amp; Medical Sciences, </institution><institution>University of Glasgow, </institution></institution-wrap>126 University Place, Glasgow, G12 8TA UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 4902 0432</institution-id><institution-id institution-id-type="GRID">grid.1005.4</institution-id><institution>The George Institute for Global Health, </institution><institution>University of New South Wales, </institution></institution-wrap>Sydney, NSW Australia </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0410 2071</institution-id><institution-id institution-id-type="GRID">grid.7737.4</institution-id><institution>Research Programs Unit, Diabetes and Obesity, </institution><institution>University of Helsinki, </institution></institution-wrap>Helsinki, Finland </aff>
                <aff id="Aff4"><label>4</label>Nightingale Health Ltd, Helsinki, Finland </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 4873</institution-id><institution-id institution-id-type="GRID">grid.10858.34</institution-id><institution>Computational Medicine, Faculty of Medicine, </institution><institution>University of Oulu and Biocenter Oulu, </institution></institution-wrap>Oulu, Finland </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0726 2490</institution-id><institution-id institution-id-type="GRID">grid.9668.1</institution-id><institution>NMR Metabolomics Laboratory, School of Pharmacy, </institution><institution>University of Eastern Finland, </institution></institution-wrap>Kuopio, Finland </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7603</institution-id><institution-id institution-id-type="GRID">grid.5337.2</institution-id><institution>Population Health Science, Bristol Medical School, University of Bristol and Medical Research Council Integrative Epidemiology Unit at the University of Bristol, </institution></institution-wrap>Bristol, UK </aff>
                <aff id="Aff8"><label>8</label>Systems Epidemiology, Baker Heart and Diabetes Institute, Melbourne, VIC Australia </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 7857</institution-id><institution-id institution-id-type="GRID">grid.1002.3</institution-id><institution>Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences, The Alfred Hospital, Monash University, </institution></institution-wrap>Melbourne, VIC Australia </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.417925.c</institution-id><institution>Inserm, UMRS 1138, Centre de Recherche des Cordeliers, </institution></institution-wrap>Paris, France </aff>
                <aff id="Aff11"><label>11</label>Assistance Publique HÃ´pitaux de Paris, Bichat Hospital, DHU FIRE, Department of Diabetology, Endocrinology and Nutrition, Paris, France </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2217 0017</institution-id><institution-id institution-id-type="GRID">grid.7452.4</institution-id><institution>University Paris Diderot, Sorbonne Paris CitÃ©, UFR de MÃ©decine, </institution></institution-wrap>Paris, France </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2113 8111</institution-id><institution-id institution-id-type="GRID">grid.7445.2</institution-id><institution>International Centre for Circulatory Health, Imperial College, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8649</institution-id><institution-id institution-id-type="GRID">grid.14709.3b</institution-id><institution>Department of Experimental Medicine, </institution><institution>McGill University, </institution></institution-wrap>Montreal, QC Canada </aff>
                <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2292 3357</institution-id><institution-id institution-id-type="GRID">grid.14848.31</institution-id><institution>Department of Medicine, CRCHUM, </institution><institution>UniversitÃ© de MontrÃ©al, </institution></institution-wrap>Montreal, QC Canada </aff>
                <aff id="Aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2292 3357</institution-id><institution-id institution-id-type="GRID">grid.14848.31</institution-id><institution>Department of Medicine, Gene Medicine Services, CRCHUM, UniversitÃ© de MontrÃ©al, </institution></institution-wrap>Montreal, QC Canada </aff>
                <aff id="Aff17"><label>17</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution>The George Institute for Global Health, University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
                <aff id="Aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution>Department of Epidemiology, Johns Hopkins University, </institution></institution-wrap>Baltimore, MD USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>4</day>
                <month>5</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>4</day>
                <month>5</month>
                <year>2018</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2018</year>
              </pub-date>
              <volume>61</volume>
              <issue>7</issue>
              <fpage>1581</fpage>
              <lpage>1591</lpage>
              <history>
                <date date-type="received">
                  <day>5</day>
                  <month>1</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>3</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© The Author(s) 2018</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Aims/hypotheses</title>
                  <p id="Par1">We aimed to quantify the association of individual circulating amino acids with macrovascular disease, microvascular disease and all-cause mortality in individuals with type 2 diabetes.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">We performed a case-cohort study (<italic>N</italic>â=â3587), including 655 macrovascular events, 342 microvascular events (new or worsening nephropathy or retinopathy) and 632 all-cause mortality events during follow-up, in a secondary analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study. For this study, phenylalanine, isoleucine, glutamine, leucine, alanine, tyrosine, histidine and valine were measured in stored plasma samples by proton NMR metabolomics. Hazard ratios were modelled per SD increase in each amino acid.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">In models investigating associations and potential mechanisms, after adjusting for age, sex and randomised treatment, phenylalanine was positively, and histidine inversely, associated with macrovascular disease risk. These associations were attenuated to the null on further adjustment for extended classical risk factors (including eGFR and urinary albumin/creatinine ratio). After adjustment for extended classical risk factors, higher tyrosine and alanine levels were associated with decreased risk of microvascular disease (HR 0.78; 95% CI 0.67, 0.91 and HR 0.86; 95% CI 0.76, 0.98, respectively). Higher leucine (HR 0.79; 95% CI 0.69, 0.90), histidine (HR 0.89; 95% CI 0.81, 0.99) and valine (HR 0.79; 95% CI 0.70, 0.88) levels were associated with lower risk of mortality. Investigating the predictive ability of amino acids, addition of all amino acids to a risk score modestly improved classification of participants for macrovascular (continuous net reclassification index [NRI] +35.5%, <italic>p</italic>â&lt;â0.001) and microvascular events (continuous NRI +14.4%, <italic>p</italic>â=â0.012).</p>
                </sec>
                <sec>
                  <title>Conclusions/interpretation</title>
                  <p id="Par4">We report distinct associations between circulating amino acids and risk of different major complications of diabetes. Low tyrosine appears to be a marker of microvascular risk in individuals with type 2 diabetes independently of fundamental markers of kidney function.</p>
                </sec>
                <sec>
                  <title>Electronic supplementary material</title>
                  <p>The online version of this article (10.1007/s00125-018-4619-x) contains peer-reviewed but unedited supplementary material, which is available to authorised users.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Amino acid</kwd>
                <kwd>Diabetes complications</kwd>
                <kwd>Metabolomics</kwd>
                <kwd>Risk factors</kwd>
                <kwd>Type 2 diabetes</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002341</institution-id>
                      <institution>Suomen Akatemia</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>312476 and 312477</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>Project grant ID 211086 and program grants IDs 358</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007919</institution-id>
                      <institution>Chest Heart and Stroke Scotland</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R13/A149</award-id>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id>
                      <institution>Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>MR/N005813/1</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>Â© Springer-Verlag GmbH Germany, part of Springer Nature 2018</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <graphic position="anchor" xlink:href="125_2018_4619_Figa_HTML" id="MO1"/>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par14">Prior to an individual developing overt type 2 diabetes, there appears to be a period of subclinical metabolic abnormality, manifesting in the altered circulating levels of many metabolites [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Specifically, several studies have now reported that circulating concentrations of amino acids predict the development of type 2 diabetes. A nested caseâcontrol study from the Framingham Offspring study showed that branched-chain amino acids (BCAAs) isoleucine, leucine and valine and aromatic amino acids (AAAs) tyrosine and phenylalanine showed positive associations with insulin resistance and risk of type 2 diabetes [<xref ref-type="bibr" rid="CR3">3</xref>]. The European Investigation into Cancer and Nutrition (EPIC) Potsdam study, the Metabolic Syndrome in Men (METSIM) study, the Cardiovascular Risk in Young Finns (CRY) study and the Southall and Brent Revisited (SABRE) study reported similar findings [<xref ref-type="bibr" rid="CR4">4</xref>â<xref ref-type="bibr" rid="CR7">7</xref>]. Glycine and glutamine have also been reported to be consistently inversely associated with risk of type 2 diabetes in a meta-analysis [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
              <p id="Par15">In general population studies, elevated levels of BCAAs and AAAs also appear to be associated with increased risk of cardiovascular disease [<xref ref-type="bibr" rid="CR9">9</xref>â<xref ref-type="bibr" rid="CR12">12</xref>], although these associations have not been entirely consistent [<xref ref-type="bibr" rid="CR13">13</xref>]. In the large Estonian Biobank study, inverse associations between the concentration of several amino acids (including BCAAs) and all-cause mortality were observed [<xref ref-type="bibr" rid="CR14">14</xref>]. An inverse association between BCAAs and clinical dementia or Alzheimerâs disease has also been observed [<xref ref-type="bibr" rid="CR15">15</xref>]. Finally, we have recently reported in a randomised placebo-controlled trial that metformin treatment (for 18Â months in men with CHD but without type 2 diabetes) led to improved insulin sensitivity and was associated with increases in alanine and histidine and reductions in phenylalanine and tyrosine concentrations, with no effect on BCAAs [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par16">Therefore, the existing literature highlights inconsistent associations of amino acids with different outcomes in different studies, apparently contrary to the observations made in general population studies wherein elevated levels of BCAAs and AAAs are an adverse signal. This raises the possibility that the mechanisms that influence circulating amino acids might be more subtle than previously thought and as such it is worth investigating and contrasting the associations of measurable circulating amino acids with different adverse outcomes in people with type 2 diabetes.</p>
              <p id="Par17">A very small (<italic>N</italic>â=â80) nested caseâcontrol study did not find that amino acids were associated with diabetic retinopathy [<xref ref-type="bibr" rid="CR17">17</xref>]. However, we are aware of no large studies investigating the association of circulating amino acids with outcomes in individuals with type 2 diabetes.</p>
              <p id="Par18">Developing an understanding of any relationship between amino acids and a range of adverse outcomes in diabetes is important from an aetiological perspective, to develop hypotheses for intervention studies and potentially to develop clinical risk scores. We thus aimed to simultaneously investigate the association of circulating amino acids with the following outcomes in people with type 2 diabetes: (1) macrovascular disease; (2) microvascular disease and (3) all-cause mortality.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="FPar1">
                <title>Participants</title>
                <p id="Par19">The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> registration no. NCT00145925) recruited 11,140 participants with type 2 diabetes between June 2001 and March 2003 [<xref ref-type="bibr" rid="CR18">18</xref>]. Primary outcomes of the trial have been published [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Participants were â¥55Â years of age and had been diagnosed with type 2 diabetes after the age of 30Â years. In addition, they were required to have a history of cardiovascular disease (CVD) or one or more additional cardiovascular risk factors. The trial included two randomised interventions: (1) a double-blind assessment of the efficacy of perindopril/indapamide (2Â mg/0.625Â mg for 3Â months, increasing to 4Â mg/1.25Â mg if tolerated) vs placebo and (2) an open-label evaluation of an intensive glucose-lowering regimen using modified-release gliclazide (with a target HbA<sub>1c</sub> of â¤48Â mmol/mol [6.5%]) vs standard care. Participants had their serum creatinine levels measured as part of the study protocol at baseline, 4Â months and 1Â year and annually thereafter until completion of the study, with further tests at the discretion of clinicians. Urinary albumin/creatinine ratio (ACR) was measured as part of the study protocol at baseline, 2Â years, 4Â years and completion of the study. GFR was estimated using the Modification of Diet in Renal Disease formula. Participants underwent formal eye examination and visual acuity testing at baseline, 2Â years, 4Â years and completion of the study. Each participating centre obtained ethical approval, and all participants provided written informed consent.</p>
                <p id="Par20">The primary trial outcomes were composites of major macrovascular and microvascular events that occurred during a median of 5Â years of follow-up. An independent adjudication committee validated all outcomes. Major macrovascular events were cardiovascular death, non-fatal myocardial infarction or non-fatal stroke. Major microvascular events were defined as a composite of new or worsening nephropathy or retinopathy, in turn defined as any of the following:<list list-type="order"><list-item><p id="Par21">development of macroalbuminuria (urinary ACR &gt;33.9Â mg/mmol, confirmed by two results);</p></list-item><list-item><p id="Par22">doubling of serum creatinine level to â¥200Â Î¼mol/l (with non-qualifying exceptions of terminal illness or acute illness and subsequent recovery of renal function);</p></list-item><list-item><p id="Par23">the need for renal replacement therapy due to kidney disease (in the absence of other medical causes requiring transient dialysis), or death due to renal disease;</p></list-item><list-item><p id="Par24">development of proliferative retinopathy (identified by the incidence of new blood vessels on the disc or elsewhere, vitreous haemorrhage, pre-retinal haemorrhage and fibrous proliferations on the disc or elsewhere in a participant found not to have this condition at entry);</p></list-item><list-item><p id="Par25">development of macular oedema (characterised by a retinal thickening within one disc diameter of the macular centre in a participant not found to have this condition at entry);</p></list-item><list-item><p id="Par26">occurrence of diabetes-related blindness (corrected visual acuity 3/60 or worse, persisting for â¥3Â months and known to not be due to non-diabetes-related causes in a participant found not to have this condition at entry);</p></list-item><list-item><p id="Par27">use of retinal photocoagulation therapy.</p></list-item></list></p>
                <p id="Par28">Blood samples were available from 17 out of 20 countries participating in the ADVANCE study (the exceptions were China, India and the Philippines), giving a total potential source cohort size for the study of 7376 individuals (66.2% of the overall study cohort).</p>
                <p id="Par29">To improve efficiency of the biomarker studies in the ADVANCE trial a case-cohort study has been established [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. In case-cohort studies, a random sample (called the âsubcohortâ) is drawn and phenotyped from the full cohort; this is very likely to contain both individuals who are âcasesâ and ânon-casesâ. Cases (generally for multiple case definitions, such as microvascular disease and macrovascular disease) who were not included in the subcohort are then identified from the remainder of the cohort and were also phenotyped. The case-cohort study has several advantages over the nested caseâcontrol design, including the ability to investigate multiple endpoints simultaneously. For this case-cohort study, a random subcohort (<italic>n</italic>â=â3500) was selected from the base population, which was enriched by the addition of individuals who had a cardiovascular event, a microvascular event or died during follow-up, giving a total study size of 4197 (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow diagram for design and sample analysis in the ADVANCE study of amino acids (note microvascular, macrovascular and all-cause mortality not mutually exclusive)</p></caption><graphic xlink:href="125_2018_4619_Fig1_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="FPar2">
                <title>Proton NMR analysis</title>
                <p id="Par30">Plasma samples were obtained at baseline from all study participants when they were in an unfasted state, given that these were people with type 2 diabetes at risk of hypoglycaemic episodes. Samples were collected across sites in a pragmatic fashion (commensurate with a multinational RCT) according to local facilities. Plasma samples were separated and stored centrally at â80Â°C until measurement. The present study used a previously unthawed aliquot of plasma for <sup>1</sup>H-NMR analysis. <sup>1</sup>H-NMR spectroscopy was performed on all available EDTA plasma samples from the ADVANCE case-cohort study at baseline using a low-volume (100Â Î¼l) variation of the quantitative <sup>1</sup>H-NMR method (Nightingale Health, Helsinki, Finland) described previously [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] and reviewed [<xref ref-type="bibr" rid="CR25">25</xref>]. Sample spectra were analysed on a Bruker AVANCE III HD spectrometer to quantify a targeted list of metabolites, lipids and lipoproteins, as described previously [<xref ref-type="bibr" rid="CR25">25</xref>]. This list included eight amino acids (alanine, glutamine, histidine, isoleucine, leucine, valine, phenylalanine and tyrosine), which are detectable using the method, and are not in âcongestedâ regions of the NMR spectrum where multiple metabolites overlap. Metabolomic analyses of plasma samples tend to yield lower analyte concentrations than serum, both by NMR spectroscopy and other methods, although plasma demonstrates better stability and reproducibility [<xref ref-type="bibr" rid="CR26">26</xref>]. Samples with a low glutamine/glutamate ratio were excluded from analyses of glutamine associations. Levels of all other amino acids were consistent with published data.</p>
              </sec>
              <sec id="FPar3">
                <title>Statistical analysis</title>
                <p id="Par31">Continuous data with approximately normal distributions (including all amino acids) are presented as mean Â± SD; those with skewed distributions are presented as median (with interquartile range). Categorical data are presented as <italic>n</italic> (%). Pearson correlations were used to explore associations of the amino acids with each other. Associations of amino acids with classical risk factors were investigated across quarters of the distribution of each amino acid.</p>
                <p id="Par32">Cox regression models were fitted using the STSELPRE procedure for case-cohort analyses (StataCorp, College Station, TX, USA). Models estimated HRs for a 1 SD increase in each amino acid with each of the endpoints. Two models, with different potential confounding variables, were fitted for each amino acid/outcome combination: model 1 with age, sex, region and randomised treatment; model 2 with, additionally, a prior macrovascular complication of diabetes (myocardial infarction, stroke, hospital admission for a transient ischaemic attack or for unstable angina, coronary or peripheral revascularisation, or amputation secondary to peripheral vascular disease), duration of diabetes, current smoking, systolic blood pressure, BMI, urinary ACR, eGFR, HbA<sub>1c</sub>, plasma glucose, total cholesterol, HDL-cholesterol, triacylglycerols, aspirin or other antiplatelet agent, statin or other lipid-lowering agent, Î²-blocker, ACE inhibitor or angiotensin receptor blocker, metformin use, history of heart failure, participation in moderate and/or vigorous exercise for &gt;15Â min at least once weekly, and high-sensitivity C-reactive protein (CRP). A third adjustment model, attempting to include all amino acids in the same model, resulted in collinearity and estimates were thus not available. Non-linearity was tested by comparing the deviances of linear and categorical models and by the inclusion of polynomial components (quadratic and cubic terms). Other analyses were performed using SAS v9.2 (SAS Institute, Cary, NC, USA). All <italic>p</italic> values reported are two-sided, with the 5% threshold used to determine significance.</p>
                <p id="Par33">For the random subcohort, the ability of amino acids to discriminate between those who will and those who will not go on to suffer each of the three adverse outcomes were estimated, in the context of model 2, using <italic>c</italic> statistics for 5Â year risk, accounting for censoring. In addition, the ability of amino acids to reclassify participants according to 5Â year risk, using the continuous net reclassification index (NRI), was assessed by methods suitable for survival data, using bootstrapping [<xref ref-type="bibr" rid="CR27">27</xref>].</p>
                <p id="Par34">Primary results came from use of all available data; sensitivity analyses using only participants with complete data were also performed.</p>
              </sec>
            </sec>
            <sec id="Sec3">
              <title>Results</title>
              <sec id="FPar4">
                <title>Baseline associations</title>
                <p id="Par35">A maximum of 3587 samples had available data for at least one amino acid (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Due to the design of the multicentre study, there was some variability in sample processing time, leading to some samples having low glutamine/glutamate ratios. As such, fewer samples had a result for glutamine [<xref ref-type="bibr" rid="CR28">28</xref>]. The detected absolute concentrations of amino acids were generally comparable with data from other studies (see electronic supplementary material [ESM] Table <xref rid="MOESM1" ref-type="media">1</xref>).</p>
                <p id="Par36">In general, the amino acids showed a broad range of correlations with each other. Taking extreme examples, leucine and glutamine were not correlated (<italic>r</italic>â=â0.03, <italic>p</italic>â=â0.23) but BCAAs leucine, isoleucine and valine were highly intercorrelated (<italic>r</italic>ââ¥â0.67, <italic>p</italic>â&lt;â0.001) (Table <xref rid="Tab1" ref-type="table">1</xref>). The associations of amino acids with classical CVD risk factors are shown in ESM Tables <xref rid="MOESM1" ref-type="media">2</xref>â<xref rid="MOESM1" ref-type="media">9</xref>. Phenylalanine was positively associated with older age, baseline CVD, higher CRP and higher baseline high-sensitivity troponin T (hsTnT) and amino-terminal pro B-type natriuretic peptide (NT-proBNP). In contrast, the other AAA, tyrosine, showed inverse associations with HbA<sub>1c</sub> and ACR and a positive association with eGFR. Histidine, alanine and glutamine showed inconsistent associations with classical risk factors. The BCAAs leucine, isoleucine and valine were inversely associated with age, HDL-cholesterol and NT-proBNP but were positively associated with CVD, male sex, BMI, triacylglycerols and HbA<sub>1c</sub>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Pearson correlations (<italic>r</italic>) of the amino acids with each other</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Amino acid</th><th>Phenylalanine</th><th>Isoleucine</th><th>Glutamine</th><th>Leucine</th><th>Alanine</th><th>Tyrosine</th><th>Histidine</th></tr></thead><tbody><tr><td>Isoleucine</td><td>0.32</td><td>â</td><td/><td/><td/><td/><td/></tr><tr><td>Glutamine</td><td>â0.05</td><td>0.05</td><td>â</td><td/><td/><td/><td/></tr><tr><td>Leucine</td><td>0.34</td><td>0.89</td><td>0.03</td><td>â</td><td/><td/><td/></tr><tr><td>Alanine</td><td>0.2</td><td>0.44</td><td>0.13</td><td>0.44</td><td>â</td><td/><td/></tr><tr><td>Tyrosine</td><td>0.4</td><td>0.25</td><td>0.13</td><td>0.29</td><td>0.26</td><td>â</td><td/></tr><tr><td>Histidine</td><td>0.16</td><td>0.24</td><td>0.43</td><td>0.2</td><td>0.27</td><td>0.17</td><td>â</td></tr><tr><td>Valine</td><td>0.27</td><td>0.67</td><td>0.13</td><td>0.75</td><td>0.34</td><td>0.29</td><td>0.25</td></tr></tbody></table><table-wrap-foot><p>All correlations have <italic>p</italic> values of &lt;0.001, except for phenylalanine vs glutamine (<italic>p</italic>â=â0.02), isoleucine vs glutamine (<italic>p</italic>â=â0.03) and glutamine vs leucine (<italic>p</italic>â=â0.23)</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="FPar5">
                <title>Macrovascular disease, microvascular disease and all-cause mortality</title>
                <p id="Par37">Baseline risk factors associated with all three endpoints included male sex, increased duration of diabetes, history of macrovascular disease, higher systolic blood pressure, lower HDL-cholesterol, higher HbA<sub>1c</sub>, higher ACR and higher hsTnT and NT-proBNP (Table <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline characteristics of the cohort classified by outcome status</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th colspan="3">Macrovascular disease</th><th colspan="3">Microvascular disease</th><th colspan="3">All-cause mortality</th></tr><tr><th/><th>Yes</th><th>No</th><th><italic>p</italic> value</th><th>Yes</th><th>No</th><th><italic>p</italic> value</th><th>Yes</th><th>No</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td><italic>N</italic></td><td>655</td><td>2932</td><td/><td>342</td><td>3245</td><td/><td>632</td><td>2955</td><td/></tr><tr><td>Age, years</td><td>68.92âÂ±â6.52</td><td>66.36âÂ±â6.51</td><td>&lt;0.001</td><td>65.85âÂ±â6.38</td><td>66.93âÂ±â6.60</td><td>0.004</td><td>69.94âÂ±â6.56</td><td>66.17âÂ±â6.40</td><td>&lt;0.001</td></tr><tr><td>Male sex</td><td>451 (68.9)</td><td>1719 (58.6)</td><td>&lt;0.001</td><td>227 (66.4)</td><td>1943 (59.9)</td><td>0.020</td><td>439 (69.5)</td><td>1731 (58.6)</td><td>&lt;0.001</td></tr><tr><td colspan="10">Region</td></tr><tr><td>ââANZ/SEA</td><td>155 (23.7)</td><td>714 (24.4)</td><td>0.375</td><td>123 (36.0)</td><td>746 (23.0)</td><td>&lt;0.001</td><td>120 (19.0)</td><td>749 (25.3)</td><td>&lt;0.001</td></tr><tr><td>ââCanada</td><td>33 (5.0)</td><td>185 (6.3)</td><td/><td>28 (8.2)</td><td>190 (5.9)</td><td/><td>34 (5.4)</td><td>184 (6.2)</td><td/></tr><tr><td>ââContinental Europe</td><td>262 (40.0)</td><td>1157 (39.5)</td><td/><td>91 (26.6)</td><td>1328 (40.9)</td><td/><td>264 (41.8)</td><td>1155 (39.1)</td><td/></tr><tr><td>ââNorthern Europe</td><td>205 (31.3)</td><td>876 (29.9)</td><td/><td>100 (29.2)</td><td>981 (30.2)</td><td/><td>214 (33.9)</td><td>867 (29.3)</td><td/></tr><tr><td>Duration of diabetes, years</td><td>9.19âÂ±â7.10</td><td>7.61âÂ±â6.29</td><td>&lt;0.001</td><td>9.74âÂ±â6.89</td><td>7.71âÂ±â6.40</td><td>&lt;0.001</td><td>9.24âÂ±â7.60</td><td>7.62âÂ±â6.17</td><td>&lt;0.001</td></tr><tr><td>Current smoker</td><td>94 (14.4)</td><td>439 (15.0)</td><td>0.686</td><td>48 (14.0)</td><td>485 (14.9)</td><td>0.652</td><td>103 (16.3)</td><td>430 (14.6)</td><td>0.263</td></tr><tr><td>History of macrovascular disease</td><td>323 (49.3)</td><td>929 (31.7)</td><td>&lt;0.001</td><td>77 (22.5)</td><td>276 (8.5)</td><td>&lt;0.001</td><td>283 (44.8)</td><td>969 (32.8)</td><td>&lt;0.001</td></tr><tr><td>History of heart failure</td><td>56 (8.5)</td><td>110 (3.8)</td><td>&lt;0.001</td><td>13 (3.8)</td><td>153 (4.7)</td><td>0.445</td><td>61 (9.7)</td><td>105 (3.6)</td><td>&lt;0.001</td></tr><tr><td>Participation in moderate or vigorous activity</td><td>266 (40.6)</td><td>1470 (50.1)</td><td>&lt;0.001</td><td>164 (48.0)</td><td>1572 (48.4)</td><td>0.863</td><td>262 (41.5)</td><td>1474 (49.9)</td><td>&lt;0.001</td></tr><tr><td>Diastolic BP, mmHg</td><td>81.55âÂ±â11.41</td><td>81.63âÂ±â10.74</td><td>0.863</td><td>81.73âÂ±â11.30</td><td>81.60âÂ±â10.82</td><td>0.831</td><td>80.55âÂ±â11.70</td><td>81.84âÂ±â10.67</td><td>0.007</td></tr><tr><td>Total cholesterol, mmol/l</td><td>5.11âÂ±â1.18</td><td>5.15âÂ±â1.17</td><td>0.500</td><td>5.16âÂ±â1.08</td><td>5.14âÂ±â1.18</td><td>0.737</td><td>5.06âÂ±â1.10</td><td>5.16âÂ±â1.18</td><td>0.058</td></tr><tr><td>HDL-cholesterol, mmol/l</td><td>1.17âÂ±â0.31</td><td>1.24âÂ±â0.33</td><td>&lt;0.001</td><td>1.18âÂ±â0.31</td><td>1.23âÂ±â0.33</td><td>0.005</td><td>1.18âÂ±â0.31</td><td>1.23âÂ±â0.33</td><td>&lt;0.001</td></tr><tr><td>Triacylglycerol, mmol/l</td><td>1.63 (1.20, 2.30)</td><td>1.70 (1.20, 2.36)</td><td>0.436</td><td>1.80 (1.27, 2.60)</td><td>1.69 (1.20, 2.31)</td><td>0.01</td><td>1.61 (1.20, 2.30)</td><td>1.70 (1.20, 2.36)</td><td>0.4912</td></tr><tr><td>HbA<sub>1c</sub>, mmol/mol</td><td>59.5âÂ±â17.2</td><td>56.9âÂ±â14.8</td><td/><td>61.3âÂ±â17.5</td><td>56.9âÂ±â15.4</td><td/><td>59.3âÂ±â16.8</td><td>56.9âÂ±â15.2</td><td/></tr><tr><td>HbA<sub>1c</sub>, %</td><td>7.59âÂ±â1.60</td><td>7.36âÂ±â1.39</td><td>&lt;0.001</td><td>7.76âÂ±â1.60</td><td>7.36âÂ±â1.41</td><td>&lt;0.001</td><td>7.58âÂ±â1.58</td><td>7.36âÂ±â1.40</td><td>&lt;0.001</td></tr><tr><td>Glucose, mmol/l</td><td>8.61âÂ±â2.85</td><td>8.43âÂ±â2.68</td><td>0.115</td><td>9.04âÂ±â3.37</td><td>8.40âÂ±â2.62</td><td>&lt;0.001</td><td>8.53âÂ±â2.88</td><td>8.45âÂ±â2.67</td><td>0.453</td></tr><tr><td>Urinary ACR, mg/mmol</td><td>2.4 (1.0, 8.0)</td><td>1.5 (0.7, 4.0)</td><td>&lt;0.001</td><td>5.6 (1.6, 14.2)</td><td>1.5 (0.7, 3.8)</td><td>&lt;0.001</td><td>2.4 (0.9, 7.6)</td><td>1.5 (0.7, 4.0)</td><td>&lt;0.001</td></tr><tr><td>eGFR, ml min<sup>â1</sup> 1.73Â m<sup>â2</sup></td><td>67.68âÂ±â17.61</td><td>72.70âÂ±â16.37</td><td>&lt;0.001</td><td>69.97âÂ±â18.74</td><td>71.98âÂ±â16.48</td><td>0.034</td><td>66.58âÂ±â17.57</td><td>72.89âÂ±â16.32</td><td>&lt;0.001</td></tr><tr><td>CRP, nmol/l</td><td>19.33 (9.05, 42.38)</td><td>16.67 (8.10, 38.48)</td><td>0.012</td><td>15.71 (8.48, 32.95)</td><td>17.43 (8.29, 39.33)</td><td>0.249</td><td>19.90 (9.71, 45.81)</td><td>16.86 (8.10, 37.71)</td><td>&lt;0.001</td></tr><tr><td>hsTnT, pg/ml</td><td>9 (4, 17)</td><td>5 (1.50, 10)</td><td>&lt;0.001</td><td>7 (1.50, 13)</td><td>5 (1.50, 11)</td><td>&lt;0.001</td><td>10 (4, 18)</td><td>5 (1.50, 9)</td><td>&lt;0.001</td></tr><tr><td>NT-proBNP, pg/ml</td><td>198 (74, 479)</td><td>74 (30, 169)</td><td>&lt;0.001</td><td>107 (38, 260)</td><td>87 (34, 212)</td><td>0.010</td><td>201 (80, 506)</td><td>74 (30, 171)</td><td>&lt;0.001</td></tr><tr><td colspan="10">Medication use</td></tr><tr><td>ââAspirin or other antiplatelet agent</td><td>387 (59.1)</td><td>1380 (47.1)</td><td>&lt;0.001</td><td>171 (50.0)</td><td>1596 (49.2)</td><td>0.774</td><td>352 (55.7)</td><td>1415 (47.9)</td><td>&lt;0.001</td></tr><tr><td>ââStatin or other lipid-lowering agent</td><td>283 (43.2)</td><td>1311 (44.7)</td><td>0.484</td><td>158 (46.2)</td><td>1436 (44.3)</td><td>0.490</td><td>260 (41.1)</td><td>1334 (45.1)</td><td>0.066</td></tr><tr><td>ââÎ² blocker</td><td>211 (32.2)</td><td>881 (30.0)</td><td>0.276</td><td>96 (28.1)</td><td>996 (30.7)</td><td>0.316</td><td>196 (31.0)</td><td>896 (30.3)</td><td>0.731</td></tr><tr><td>ââACE inhibitor or angiotensin receptor blocker</td><td>418 (63.8)</td><td>1671 (57.0)</td><td>0.0014</td><td>232 (67.8)</td><td>1857 (57.2)</td><td>&lt;0.001</td><td>395 (62.5)</td><td>1694 (57.3)</td><td>0.017</td></tr><tr><td colspan="10">Amino acid level, mmol/l</td></tr><tr><td>ââPhenylalanine</td><td>0.063âÂ±â0.010</td><td>0.061âÂ±â0.009</td><td>&lt;0.001</td><td>0.062âÂ±â0.009</td><td>0.062âÂ±â0.009</td><td>0.1327</td><td>0.063âÂ±â0.010</td><td>0.061âÂ±â0.009</td><td>&lt;0.001</td></tr><tr><td>ââIsoleucine</td><td>0.063âÂ±â0.017</td><td>0.062âÂ±â0.017</td><td>0.7429</td><td>0.065âÂ±â0.017</td><td>0.062âÂ±â0.017</td><td>0.0059</td><td>0.061âÂ±â0.017</td><td>0.063âÂ±â0.017</td><td>0.0643</td></tr><tr><td>ââGlutamine</td><td>0.373âÂ±â0.112</td><td>0.380âÂ±â0.109</td><td>0.2634</td><td>0.369âÂ±â0.118</td><td>0.380âÂ±â0.109</td><td>0.1696</td><td>0.367âÂ±â0.112</td><td>0.381âÂ±â0.109</td><td>0.0247</td></tr><tr><td>ââLeucine</td><td>0.081âÂ±â0.019</td><td>0.082âÂ±â0.020</td><td>0.0679</td><td>0.084âÂ±â0.020</td><td>0.082âÂ±â0.020</td><td>0.0518</td><td>0.079âÂ±â0.020</td><td>0.082âÂ±â0.020</td><td>&lt;0.001</td></tr><tr><td>ââAlanine</td><td>0.366âÂ±â0.064</td><td>0.371âÂ±â0.065</td><td>0.0591</td><td>0.370âÂ±â0.066</td><td>0.370âÂ±â0.064</td><td>0.9372</td><td>0.361âÂ±â0.063</td><td>0.372âÂ±â0.065</td><td>&lt;0.001</td></tr><tr><td>ââTyrosine</td><td>0.053âÂ±â0.012</td><td>0.053âÂ±â0.011</td><td>0.9293</td><td>0.050âÂ±â0.012</td><td>0.053âÂ±â0.011</td><td>&lt;0.001</td><td>0.052âÂ±â0.012</td><td>0.053âÂ±â0.011</td><td>0.1873</td></tr><tr><td>ââHistidine</td><td>0.049âÂ±â0.010</td><td>0.050âÂ±â0.009</td><td>0.0032</td><td>0.050âÂ±â0.009</td><td>0.050âÂ±â0.010</td><td>0.4117</td><td>0.048âÂ±â0.010</td><td>0.050âÂ±â0.009</td><td>&lt;0.001</td></tr><tr><td>ââValine</td><td>0.172âÂ±â0.035</td><td>0.175âÂ±â0.035</td><td>0.1355</td><td>0.177âÂ±â0.037</td><td>0.174âÂ±â0.035</td><td>0.1729</td><td>0.167âÂ±â0.036</td><td>0.176âÂ±â0.035</td><td>&lt;0.001</td></tr></tbody></table><table-wrap-foot><p>Values are mean Â±SD, median (interquartile range) or <italic>n</italic> (%)</p><p>ANZ, Australia and New Zealand; SEA, south-east Asia</p></table-wrap-foot></table-wrap></p>
                <p id="Par38">Among the amino acids, after adjustment for age, sex, region and randomised treatment (model 1), higher phenylalanine and lower glutamine and histidine concentrations were associated with increased macrovascular risk (HR per 1 SD increase was 1.22 [95% CI 1.12, 1.32], 0.88 [95% CI 0.79, 0.98] and 0.86 [95% CI 0.79, 0.94], respectively) but these associations were attenuated to the null on further adjustment for classical risk factors (model 2) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a and ESM Table <xref rid="MOESM1" ref-type="media">10</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Adjusted associations (model 2, log<sub>10</sub> scale HR) of amino acids individually (per 1 SD increase) with macrovascular outcomes (<bold>a</bold>), microvascular outcomes (<bold>b</bold>) and all-cause mortality (<bold>c</bold>)</p></caption><graphic xlink:href="125_2018_4619_Fig2_HTML" id="MO3"/></fig></p>
                <p id="Par39">Higher tyrosine alone was associated with decreased risk of microvascular events (HR 0.74 [95% CI 0.64, 0.86]) in model 1 and this was only slightly attenuated on adjustment for a full range of classical risk factors in model 2 (HR 0.78 [95% CI 0.67, 0.91]) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b and ESM Table <xref rid="MOESM1" ref-type="media">10</xref>). A higher alanine level was also associated with decreased risk of microvascular events after further adjustment (HR 0.86 [95% CI 0.76, 0.98]). The association between tyrosine and renal impairment was further investigated by assessing the HRs across tertiles of eGFR and ACR. There was no evidence of interaction by eGFR or ACR (data not shown).</p>
                <p id="Par40">In contrast, several amino acids were associated with all-cause mortality. Phenylalanine was positively associated with risk of mortality, while glutamine, leucine, alanine, histidine and valine were all inversely associated with risk of mortality in model 1 (ESM Table <xref rid="MOESM1" ref-type="media">10</xref>). After adjustment for classical risk factors (model 2), the inverse association with risk remained for leucine (HR 0.79 [95% CI 0.69, 0.90]), histidine (HR 0.89 [95% CI 0.81, 0.99]) and valine (HR 0.79 [95% CI 0.70, 0.88]) but the positive association of phenylalanine was attenuated to the null (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c and ESM Table <xref rid="MOESM1" ref-type="media">10</xref>). A sensitivity analysis using samples from individuals with complete data gave similar results (ESM Table <xref rid="MOESM1" ref-type="media">11</xref>). There was no evidence of a randomised treatment interaction in any model (data not shown).</p>
                <p id="Par41">A model including all the classical CVD risk factors in model 2 yielded a <italic>c</italic> statistic of 0.716 for macrovascular events, 0.728 for microvascular events and 0.747 for all-cause mortality (Table <xref rid="Tab3" ref-type="table">3</xref>). Addition of the amino acids in combination did not improve the <italic>c</italic> statistic for any endpoint but did improve the continuous NRI for macrovascular events (+35.5%, <italic>p</italic>â&lt;â0.001) and microvascular events (+14.4%, <italic>p</italic>â=â0.012). The improvement in prediction of microvascular events was driven by the addition of tyrosine alone.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Prediction of endpoints using amino acids in combination or individually</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Model</th><th colspan="2">Macrovascular events</th><th colspan="2">Microvascular events</th><th colspan="2">All-cause mortality</th></tr><tr><th/><th><italic>c</italic> statistic</th><th>Continuous NRI (%)</th><th><italic>c</italic> statistic</th><th>Continuous NRI (%)</th><th><italic>c</italic> statistic</th><th>Continuous NRI (%)</th></tr></thead><tbody><tr><td>Basic model<sup>a</sup></td><td>0.716</td><td>â</td><td>0.728</td><td>â</td><td>0.747</td><td>â</td></tr><tr><td>Plus all amino acids</td><td>+0.010</td><td>+35.5</td><td>+0.010</td><td>+14.4</td><td>+0.009</td><td>+8.0</td></tr><tr><td>ââ<italic>p</italic> value</td><td>0.17</td><td>&lt;0.001</td><td>0.23</td><td>0.012</td><td>0.26</td><td>0.09</td></tr><tr><td>Plus tyrosine only</td><td>â</td><td>â</td><td>0.007</td><td>+14.9</td><td>â</td><td>â</td></tr><tr><td>ââ<italic>p</italic> value</td><td>â</td><td>â</td><td>0.30</td><td>0.01</td><td>â</td><td>â</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Adjusted for age, sex, region, randomised treatment, previous macrovascular event, duration of diabetes, current smoking, systolic blood pressure, BMI, urinary ACR, eGFR, HbA<sub>1c</sub>, plasma glucose, total and HDL-cholesterol, triacylglycerols, use of aspirin or other antiplatelet agent, statin or other lipid-lowering agent, Î²-blocker, ACE inhibitor or angiotensin receptor blocker, or metformin, history of heart failure, participation in moderate and/or vigorous exercise for &gt;15Â min at least once weekly, and CRP</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec4">
              <title>Discussion</title>
              <p id="Par42">Although previous observational studies have reported associations of circulating BCAAs and AAAs with adverse outcomes in healthy people, the present report contrasts for the first time the associations of multiple circulating amino acids with the major vascular complications of diabetes. Rather than one (or more) amino acids being a consistent signal for adverse outcomes of any kind, we report that their associations with risk of macrovascular events, microvascular events and all-cause mortality are strikingly different from each other. A key finding is the inverse association of tyrosine with risk of microvascular events, independent of eGFR and urinary ACR. Although the evidence from the present study suggests that these might only be very moderately useful biomarkers in incremental prediction of adverse events in individuals with type 2 diabetes, the pathophysiology underlying these associations and the possibility of intervention studies are intriguing and worthy of further investigation.</p>
              <p id="Par43">The association of high circulating concentrations of BCAAs and AAAs with obesity has been known since the 1960s [<xref ref-type="bibr" rid="CR29">29</xref>] and has been proposed to be at least partially mediated by insulin resistance. Insulin is thought to be a regulator of branched-chain Î±-keto acid dehydrogenase complex [<xref ref-type="bibr" rid="CR30">30</xref>]. Insulin resistance may hence suppress BCAA catabolism, as suggested by associations noted in observational epidemiology studies [<xref ref-type="bibr" rid="CR31">31</xref>â<xref ref-type="bibr" rid="CR33">33</xref>]. The causal pathway may not be unidirectional; a recent Mendelian randomisation study suggests that genetically elevated BCAAs (via impaired catabolism) are associated with increased risk of type 2 diabetes [<xref ref-type="bibr" rid="CR34">34</xref>], although a better understanding of the underlying pathway is required to increase confidence in this observation [<xref ref-type="bibr" rid="CR35">35</xref>]. There is also the possibility that amino acids themselves (particularly BCAAs) may affect metabolism by suppressing postprandial glucose levels [<xref ref-type="bibr" rid="CR36">36</xref>]. Increased protein turnover in people with central obesity may result in higher circulating levels of amino acids [<xref ref-type="bibr" rid="CR37">37</xref>] and might therefore cause elevations in amino acids in people who are overweight and have type 2 diabetes. There are hence a variety of potential mechanisms related to type 2 diabetes pathologies that might influence circulating amino acids in individuals with type 2 diabetes.</p>
              <p id="Par44">Given this background, and prior findings in general populations of associations of specific amino acids with CVD [<xref ref-type="bibr" rid="CR9">9</xref>â<xref ref-type="bibr" rid="CR12">12</xref>], we wished to examine whether amino acid levels associated with adverse outcomes in individuals with type 2 diabetes. In the ADVANCE study, the BCAAs leucine, valine and isoleucine showed no association with macrovascular events, but low levels of leucine and valine were associated with increased all-cause mortality. However, the positive, albeit not independently predictive, association of phenylalanine with CVD and all-cause mortality we observed is broadly in line with other published data. There are limited intervention studies investigating the effect of amino acid supplements on health outcomes, with most research coming from short-term trials examining surrogate health markers in the sports science area [<xref ref-type="bibr" rid="CR38">38</xref>]. Our data strongly support the need for further studies to determine why higher phenylalanine appears to be a consistently adverse signal for CVD outcomes. Our study provides observations that are the basis for testable hypotheses investigating the effect of genetic variants, which are instrumental variables for circulating amino acids, on health outcomes [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p>
              <p id="Par45">The inverse association of tyrosine with risk of microvascular events is perhaps the most intriguing individual finding from this study. Tyrosine itself was positively associated with baseline eGFR and inversely associated with baseline HbA<sub>1c</sub> and urinary ACR. Impaired conversion of phenylalanine to tyrosine has been reported in renal disease [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Low tyrosine levels might therefore simply reflect impaired kidney function, which itself predicts future microvascular events. Tyrosine is also linked to catecholamine synthesis, which, also speculatively, might be relevant to our findings [<xref ref-type="bibr" rid="CR43">43</xref>]. That noted, counter-intuitively, we have reported that metformin in fact lowers, not raises, tyrosine levels in individuals with CVD and at high risk of diabetes [<xref ref-type="bibr" rid="CR16">16</xref>]. The effect of other glucose-lowering drugs on amino acid profiles in individuals with diabetes would now be of interest. Further studies are now needed to validate our novel observations and to examine whether our findings may represent causal pathways.</p>
              <p id="Par46">Strengths of the study include the use of a well-characterised clinical trial cohort, an efficiently designed case-cohort study to yield a powerful study for a range of endpoints, which were independently adjudicated according to pre-defined criteria. Like other RCT populations, ADVANCE study participants represent a selected cohort. For instance, ADVANCE study participants were required to have a history of CVD or CVD risk factors. Therefore, our results may not be generalisable to all individuals with diabetes, although other risk factors we measured are generally associated with risk of major endpoints in the expected directions. Amino acids were measured in pragmatically collected plasma samples in the context of a multinational RCT and we cannot rule out the potential for differential pre-analytical sample handling or sample degradation during storage, which may have biased our results [<xref ref-type="bibr" rid="CR44">44</xref>], although these samples were analysed at first thaw. We also present data suggesting broadly comparable concentrations of amino acids relative to other cohorts. Another potential limitation is the analysis of samples from non-fasted participants, although in clinical practice, fasting is rarely required among individuals with type 2 diabetes. NMR spectroscopy has been used to investigate changes in amino acids 30Â min after a standardised liquid meal [<xref ref-type="bibr" rid="CR45">45</xref>] and effects sizes were generally relatively small, although the immediate postprandial state is likely to give larger effect estimates than are at play in this study.</p>
              <p id="Par47">In conclusion, we report distinct associations of different amino acids with risk of major adverse endpoints in individuals with type 2 diabetes. Most notably, the identification of tyrosine as a potential marker of microvascular risk requires further study.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Electronic supplementary material</title>
              <sec id="Sec5">
                <p>
                  <supplementary-material content-type="local-data" id="MOESM1">
                    <media xlink:href="125_2018_4619_MOESM1_ESM.pdf">
                      <label>ESM Tables</label>
                      <caption>
                        <p>(PDF 659 kb)</p>
                      </caption>
                    </media>
                  </supplementary-material>
                </p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>AAA</term>
                  <def>
                    <p id="Par5">Aromatic amino acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ACR</term>
                  <def>
                    <p id="Par6">Albumin/creatinine ratio</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ADVANCE</term>
                  <def>
                    <p id="Par7">Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BCAA</term>
                  <def>
                    <p id="Par8">Branched-chain amino acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CRP</term>
                  <def>
                    <p id="Par9">C-reactive protein</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CVD</term>
                  <def>
                    <p id="Par10">Cardiovascular disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>hsTnT</term>
                  <def>
                    <p id="Par11">High-sensitivity troponin T</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NRI</term>
                  <def>
                    <p id="Par12">Net reclassification index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NT-proBNP</term>
                  <def>
                    <p id="Par13">Amino-terminal pro B-type natriuretic peptide</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>Paul Welsh and Naomi Rankin are joint first authors. Mark Woodward and Naveed Sattar are joint senior authors.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We thank E. Butler, University of Glasgow, UK for technical assistance in conducting the study.</p>
              <sec id="FPar6">
                <title>Contribution statement</title>
                <p id="Par48">MM, NP, PH, MW and JC conceived, designed and acquired the ADVANCE trial data. PWe, MW, NR, PM and NS conceived this secondary study, and PWe and NS obtained grant funding. PWu and MA-K acquired biomarker data. MW and QL undertook the statistical analyses. All authors were involved in data interpretation. PWe and NR wrote the initial drafts of the manuscript. These drafts were revised for important scientific content by MW, NS, PM, PWu, MA-K, QL, MM, NP, PH, and JC. All authors gave final approval of the version to be published. MW is the guarantor of this work.</p>
              </sec>
            </ack>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>The biomarker work in the present study was funded by the Chest Heart and Stroke Association Scotland (R13/A149) and by the Glasgow Molecular Pathology NODE, which is funded by The Medical Research Council and The Engineering and Physical Sciences Research Council (MR/N005813/1). The ADVANCE trial (<ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> registration no. NCT00145925) was funded by the National Health and Medical Research Council (NHMRC) of Australia (project grant ID 211086 and program grant IDs 358395 and 571281) and by Servier. PWu is supported by the Academy of Finland (312476 and 312477) and the Novo Nordisk Foundation. MAK was supported by the Sigrid Juselius Foundation, Finland. MAK works in a Unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_12013/1). The study sponsors were not involved in the design of the study, the collection, analysis, and interpretation of data, writing the report or the decision to submit the report for publication.</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Summaries of the ADVANCE trial data can be found at <ext-link ext-link-type="uri" xlink:href="http://www.advance-trial.com">http://www.advance-trial.com</ext-link>. Restrictions apply to the availability of these data, which were used by agreement of the ADVANCE steering committee for the current study, and so are not publicly available.</p>
            </notes>
            <notes notes-type="COI-statement">
              <title>Duality of interest</title>
              <p>JC has received Research grants from Servier as Principal investigator for ADVANCE and for the ADVANCE-ON post trial follow-up study and honoraria from Servier for speaking about these studies at scientific meetings. MW reports receiving consulting fees from Amgen. PWu is an employee and shareholder of Nightingale Health Ltd, which conducted the biomarker quantification. All other authors declare that there is no duality of interest associated with their contribution to this paper.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gaillard</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Osei</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes</article-title>
                  <source>BMJ Open Diabetes Res Care</source>
                  <year>2016</year>
                  <volume>4</volume>
                  <fpage>e000246</fpage>
                  <pub-id pub-id-type="doi">10.1136/bmjdrc-2016-000246</pub-id>
                  <?supplied-pmid 27547417?>
                  <pub-id pub-id-type="pmid">27547417</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liggi</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Griffin</surname>
                      <given-names>JL</given-names>
                    </name>
                  </person-group>
                  <article-title>Metabolomics applied to diabetes-lessons from human population studies</article-title>
                  <source>Int J Biochem Cell Biol</source>
                  <year>2017</year>
                  <volume>93</volume>
                  <fpage>136</fpage>
                  <lpage>147</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.biocel.2017.10.011</pub-id>
                  <?supplied-pmid 29074437?>
                  <pub-id pub-id-type="pmid">29074437</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wang</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Larson</surname>
                      <given-names>MG</given-names>
                    </name>
                    <name>
                      <surname>Vasan</surname>
                      <given-names>RS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolite profiles and the risk of developing diabetes</article-title>
                  <source>Nat Med</source>
                  <year>2011</year>
                  <volume>17</volume>
                  <fpage>448</fpage>
                  <lpage>453</lpage>
                  <pub-id pub-id-type="doi">10.1038/nm.2307</pub-id>
                  <?supplied-pmid 21423183?>
                  <pub-id pub-id-type="pmid">21423183</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Floegel</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Stefan</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>MÃ¼hlenbruch</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach</article-title>
                  <source>Diabetes</source>
                  <year>2013</year>
                  <volume>62</volume>
                  <fpage>639</fpage>
                  <lpage>648</lpage>
                  <pub-id pub-id-type="doi">10.2337/db12-0495</pub-id>
                  <?supplied-pmid 23043162?>
                  <pub-id pub-id-type="pmid">23043162</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tillin</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hughes</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Diabetes risk and amino acid profiles: cross-sectional and prospective analyses of ethnicity, amino acids and diabetes in a South Asian and European cohort from the SABRE (Southall And Brent REvisited) Study</article-title>
                  <source>Diabetologia</source>
                  <year>2015</year>
                  <volume>58</volume>
                  <fpage>968</fpage>
                  <lpage>979</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-015-3517-8</pub-id>
                  <?supplied-pmid 25693751?>
                  <pub-id pub-id-type="pmid">25693751</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>WÃ¼rtz</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Soininen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kangas</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults</article-title>
                  <source>Diabetes Care</source>
                  <year>2013</year>
                  <volume>36</volume>
                  <fpage>648</fpage>
                  <lpage>655</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc12-0895</pub-id>
                  <?supplied-pmid 23129134?>
                  <pub-id pub-id-type="pmid">23129134</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stancakova</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Civelek</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Saleem</surname>
                      <given-names>NK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9,369 Finnish Men</article-title>
                  <source>Diabetes</source>
                  <year>2012</year>
                  <volume>61</volume>
                  <fpage>1895</fpage>
                  <lpage>1902</lpage>
                  <pub-id pub-id-type="doi">10.2337/db11-1378</pub-id>
                  <?supplied-pmid 22553379?>
                  <pub-id pub-id-type="pmid">22553379</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Guasch-FerrÃ©</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hruby</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Toledo</surname>
                      <given-names>E</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolomics in prediabetes and diabetes: a systematic review and meta-analysis</article-title>
                  <source>Diabetes Care</source>
                  <year>2016</year>
                  <volume>39</volume>
                  <fpage>833</fpage>
                  <lpage>846</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc15-2251</pub-id>
                  <?supplied-pmid 27208380?>
                  <pub-id pub-id-type="pmid">27208380</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>WÃ¼rtz</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Havulinna</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Soininen</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts</article-title>
                  <source>Circulation</source>
                  <year>2015</year>
                  <volume>131</volume>
                  <fpage>774</fpage>
                  <lpage>785</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.013116</pub-id>
                  <?supplied-pmid 25573147?>
                  <pub-id pub-id-type="pmid">25573147</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shah</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Bain</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Muehlbauer</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events</article-title>
                  <source>Circ Cardiovasc Genet</source>
                  <year>2010</year>
                  <volume>3</volume>
                  <fpage>207</fpage>
                  <lpage>214</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCGENETICS.109.852814</pub-id>
                  <?supplied-pmid 20173117?>
                  <pub-id pub-id-type="pmid">20173117</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Magnusson</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Ericson</surname>
                      <given-names>U</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A diabetes-predictive amino acid score and future cardiovascular disease</article-title>
                  <source>Eur Heart J</source>
                  <year>2013</year>
                  <volume>34</volume>
                  <fpage>1982</fpage>
                  <lpage>1989</lpage>
                  <pub-id pub-id-type="doi">10.1093/eurheartj/ehs424</pub-id>
                  <?supplied-pmid 23242195?>
                  <pub-id pub-id-type="pmid">23242195</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ruiz-Canela</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Toledo</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Clish</surname>
                      <given-names>CB</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma branched-chain amino acids and incident cardiovascular disease in the PREDIMED trial</article-title>
                  <source>Clin Chem</source>
                  <year>2016</year>
                  <volume>62</volume>
                  <fpage>582</fpage>
                  <lpage>592</lpage>
                  <pub-id pub-id-type="doi">10.1373/clinchem.2015.251710</pub-id>
                  <?supplied-pmid 26888892?>
                  <pub-id pub-id-type="pmid">26888892</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Floegel</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>KÃ¼hn</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Sookthai</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Serum metabolites and risk of myocardial infarction and ischemic stroke: a targeted metabolomic approach in two German prospective cohorts</article-title>
                  <source>Eur J Epidemiol</source>
                  <year>2018</year>
                  <volume>33</volume>
                  <fpage>55</fpage>
                  <lpage>66</lpage>
                  <pub-id pub-id-type="doi">10.1007/s10654-017-0333-0</pub-id>
                  <?supplied-pmid 29181692?>
                  <pub-id pub-id-type="pmid">29181692</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fischer</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kettunen</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>WÃ¼rtz</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons</article-title>
                  <source>PLoS Med</source>
                  <year>2014</year>
                  <volume>11</volume>
                  <fpage>e1001606</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pmed.1001606</pub-id>
                  <?supplied-pmid 24586121?>
                  <pub-id pub-id-type="pmid">24586121</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <mixed-citation publication-type="other">Tynkkynen J, Chouraki V, Van der Lee S et al (2018) Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and AlzheimerÊ¼s disease: a prospective study in eight cohorts. Alzheimers Dement. 10.1016/j.jalz.2018.01.003</mixed-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Preiss</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Rankin</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Welsh</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effect of metformin therapy on circulating amino acids in a randomized trial: the CAMERA study</article-title>
                  <source>Diabet Med</source>
                  <year>2016</year>
                  <volume>33</volume>
                  <fpage>1569</fpage>
                  <lpage>1574</lpage>
                  <pub-id pub-id-type="doi">10.1111/dme.13097</pub-id>
                  <?supplied-pmid 26887663?>
                  <pub-id pub-id-type="pmid">26887663</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Chen</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Choi</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Plasma metabonomic profiling of diabetic retinopathy</article-title>
                  <source>Diabetes</source>
                  <year>2016</year>
                  <volume>65</volume>
                  <fpage>1099</fpage>
                  <lpage>1108</lpage>
                  <pub-id pub-id-type="doi">10.2337/db15-0661</pub-id>
                  <?supplied-pmid 26822086?>
                  <pub-id pub-id-type="pmid">26822086</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <mixed-citation publication-type="other">ADVANCE Management Committee (2001) Study rationale and design of ADVANCE: Action in Diabetes and Vascular disease â Preterax and Diamicron MR Controlled Evaluation. Diabetologia 44:1118â1120</mixed-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>ADVANCE Collaborative Group</collab>
                    <name>
                      <surname>Patel</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>MacMahon</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title>
                  <source>N Engl J Med</source>
                  <year>2008</year>
                  <volume>358</volume>
                  <fpage>2560</fpage>
                  <lpage>2572</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa0802987</pub-id>
                  <pub-id pub-id-type="pmid">18539916</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Patel</surname>
                      <given-names>A</given-names>
                    </name>
                    <collab>ADVANCE Collaborative Group</collab>
                    <name>
                      <surname>MacMahon</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <year>2007</year>
                  <volume>370</volume>
                  <fpage>829</fpage>
                  <lpage>840</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(07)61303-8</pub-id>
                  <?supplied-pmid 17765963?>
                  <pub-id pub-id-type="pmid">17765963</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hillis</surname>
                      <given-names>GS</given-names>
                    </name>
                    <name>
                      <surname>Welsh</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Chalmers</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes</article-title>
                  <source>Diabetes Care</source>
                  <year>2014</year>
                  <volume>37</volume>
                  <fpage>295</fpage>
                  <lpage>303</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc13-1165</pub-id>
                  <?supplied-pmid 24089534?>
                  <pub-id pub-id-type="pmid">24089534</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Welsh</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Woodward</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Hillis</surname>
                      <given-names>GS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial</article-title>
                  <source>Diabetes Care</source>
                  <year>2014</year>
                  <volume>37</volume>
                  <fpage>2202</fpage>
                  <lpage>2210</lpage>
                  <pub-id pub-id-type="doi">10.2337/dc13-2625</pub-id>
                  <?supplied-pmid 24879844?>
                  <pub-id pub-id-type="pmid">24879844</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>WÃ¼rtz</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kangas</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Soininen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lawlor</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Davey Smith</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ala-Korpela</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technology</article-title>
                  <source>Am J Epidemiol</source>
                  <year>2017</year>
                  <volume>186</volume>
                  <fpage>1084</fpage>
                  <lpage>1096</lpage>
                  <pub-id pub-id-type="doi">10.1093/aje/kwx016</pub-id>
                  <?supplied-pmid 29106475?>
                  <pub-id pub-id-type="pmid">29106475</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Soininen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kangas</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>WÃ¼rtz</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism</article-title>
                  <source>Analyst</source>
                  <year>2009</year>
                  <volume>134</volume>
                  <fpage>1781</fpage>
                  <lpage>1785</lpage>
                  <pub-id pub-id-type="doi">10.1039/b910205a</pub-id>
                  <?supplied-pmid 19684899?>
                  <pub-id pub-id-type="pmid">19684899</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Soininen</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kangas</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>WÃ¼rtz</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Suna</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Ala-Korpela</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics</article-title>
                  <source>Circ Cardiovasc Genet</source>
                  <year>2015</year>
                  <volume>8</volume>
                  <fpage>192</fpage>
                  <lpage>206</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCGENETICS.114.000216</pub-id>
                  <?supplied-pmid 25691689?>
                  <pub-id pub-id-type="pmid">25691689</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>KastenmÃ¼ller</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>He</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Differences between human plasma and serum metabolite profiles</article-title>
                  <source>PLoS One</source>
                  <year>2011</year>
                  <volume>6</volume>
                  <fpage>e21230</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0021230</pub-id>
                  <?supplied-pmid 21760889?>
                  <pub-id pub-id-type="pmid">21760889</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pencina</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>DâAgostino</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Steyerberg</surname>
                      <given-names>EW</given-names>
                    </name>
                  </person-group>
                  <article-title>Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers</article-title>
                  <source>Stat Med</source>
                  <year>2011</year>
                  <volume>30</volume>
                  <fpage>11</fpage>
                  <lpage>21</lpage>
                  <pub-id pub-id-type="doi">10.1002/sim.4085</pub-id>
                  <?supplied-pmid 21204120?>
                  <pub-id pub-id-type="pmid">21204120</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Grossie</surname>
                      <given-names>VB</given-names>
                    </name>
                    <name>
                      <surname>Yick</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Alpeter</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Welbourne</surname>
                      <given-names>TC</given-names>
                    </name>
                    <name>
                      <surname>Ota</surname>
                      <given-names>DM</given-names>
                    </name>
                  </person-group>
                  <article-title>Glutamine stability in biological tissues evaluated by fluorometric analysis</article-title>
                  <source>Clin Chem</source>
                  <year>1993</year>
                  <volume>39</volume>
                  <fpage>1059</fpage>
                  <lpage>1063</lpage>
                  <?supplied-pmid 8504538?>
                  <pub-id pub-id-type="pmid">8504538</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Felig</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Marliss</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Cahill</surname>
                      <given-names>GF</given-names>
                    </name>
                  </person-group>
                  <article-title>Plasma amino acid levels and insulin secretion in obesity</article-title>
                  <source>N Engl J Med</source>
                  <year>1969</year>
                  <volume>281</volume>
                  <fpage>811</fpage>
                  <lpage>816</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJM196910092811503</pub-id>
                  <?supplied-pmid 5809519?>
                  <pub-id pub-id-type="pmid">5809519</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Costeas</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Chinsky</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Effects of insulin on the regulation of branched-chain Î±-keto acid dehydrogenase E1Î± subunit gene expression</article-title>
                  <source>Biochem J</source>
                  <year>1996</year>
                  <volume>318</volume>
                  <fpage>85</fpage>
                  <lpage>92</lpage>
                  <pub-id pub-id-type="doi">10.1042/bj3180085</pub-id>
                  <?supplied-pmid 8761456?>
                  <pub-id pub-id-type="pmid">8761456</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shah</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Crosslin</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Haynes</surname>
                      <given-names>CS</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Branched-chain amino acid levels are associated with improvement in insulin resistance with weight loss</article-title>
                  <source>Diabetologia</source>
                  <year>2012</year>
                  <volume>55</volume>
                  <fpage>321</fpage>
                  <lpage>330</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-011-2356-5</pub-id>
                  <?supplied-pmid 22065088?>
                  <pub-id pub-id-type="pmid">22065088</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McCormack</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Shaham</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>McCarthy</surname>
                      <given-names>MA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Circulating branched-chain amino acid concentrations are associated with obesity and future insulin resistance in children and adolescents</article-title>
                  <source>Pediatr Obes</source>
                  <year>2013</year>
                  <volume>8</volume>
                  <fpage>52</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.2047-6310.2012.00087.x</pub-id>
                  <?supplied-pmid 22961720?>
                  <pub-id pub-id-type="pmid">22961720</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <mixed-citation publication-type="other">WÃ¼rtz P, Wang Q, Kangas AJ et al (2014) Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS Med 11:e1001765</mixed-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lotta</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Scott</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Sharp</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Genetic predisposition to an impaired metabolism of the branched-chain amino acids and risk of type 2 diabetes: a Mendelian randomisation analysis</article-title>
                  <source>PLoS Med</source>
                  <year>2016</year>
                  <volume>13</volume>
                  <fpage>e1002179</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pmed.1002179</pub-id>
                  <?supplied-pmid 27898682?>
                  <pub-id pub-id-type="pmid">27898682</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holmes</surname>
                      <given-names>MV</given-names>
                    </name>
                    <name>
                      <surname>Ala-Korpela</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>GD</given-names>
                    </name>
                  </person-group>
                  <article-title>Mendelian randomization in cardiometabolic disease: challenges in evaluating causality</article-title>
                  <source>Nat Rev Cardiol</source>
                  <year>2017</year>
                  <volume>14</volume>
                  <fpage>577</fpage>
                  <lpage>590</lpage>
                  <pub-id pub-id-type="doi">10.1038/nrcardio.2017.78</pub-id>
                  <?supplied-pmid 28569269?>
                  <pub-id pub-id-type="pmid">28569269</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Manders</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>Little</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Forbes</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Candow</surname>
                      <given-names>DG</given-names>
                    </name>
                  </person-group>
                  <article-title>Insulinotropic and muscle protein synthetic effects of branched-chain amino acids: potential therapy for type 2 diabetes and sarcopenia</article-title>
                  <source>Nutrients</source>
                  <year>2012</year>
                  <volume>4</volume>
                  <fpage>1664</fpage>
                  <lpage>1678</lpage>
                  <pub-id pub-id-type="doi">10.3390/nu4111664</pub-id>
                  <?supplied-pmid 23201839?>
                  <pub-id pub-id-type="pmid">23201839</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tai</surname>
                      <given-names>ES</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>MLS</given-names>
                    </name>
                    <name>
                      <surname>Stevens</surname>
                      <given-names>RD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men</article-title>
                  <source>Diabetologia</source>
                  <year>2010</year>
                  <volume>53</volume>
                  <fpage>757</fpage>
                  <lpage>767</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00125-009-1637-8</pub-id>
                  <?supplied-pmid 20076942?>
                  <pub-id pub-id-type="pmid">20076942</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Tan</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Gui</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>Y</given-names>
                    </name>
                  </person-group>
                  <article-title>Clinical effectiveness of protein and amino acid supplementation on building muscle mass in elderly people: a meta-analysis</article-title>
                  <source>PLoS One</source>
                  <year>2014</year>
                  <volume>e10</volume>
                  <fpage>9141</fpage>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yu</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>de Vries</surname>
                      <given-names>PS</given-names>
                    </name>
                    <name>
                      <surname>Metcalf</surname>
                      <given-names>GA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Whole genome sequence analysis of serum amino acid levels</article-title>
                  <source>Genome Biol</source>
                  <year>2016</year>
                  <volume>17</volume>
                  <fpage>237</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13059-016-1106-x</pub-id>
                  <?supplied-pmid 27884205?>
                  <pub-id pub-id-type="pmid">27884205</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <mixed-citation publication-type="other">Teslovich TM, Kim DS, Yin X et al (2018) Identification of seven novel loci associated with amino acid levels using single variant and gene-based tests in 8545 Finnish men from the METSIM study. Hum Mol Genet. 27:1664â1674</mixed-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kopple</surname>
                      <given-names>JD</given-names>
                    </name>
                  </person-group>
                  <article-title>Phenylalanine and tyrosine metabolism in chronic kidney failure</article-title>
                  <source>J Nutr</source>
                  <year>2007</year>
                  <volume>137</volume>
                  <fpage>1586S</fpage>
                  <lpage>1590S</lpage>
                  <pub-id pub-id-type="doi">10.1093/jn/137.6.1586S</pub-id>
                  <?supplied-pmid 17513431?>
                  <pub-id pub-id-type="pmid">17513431</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Druml</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Roth</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Lenz</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lochs</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Kopsa</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Phenylalanine and tyrosine metabolism in renal failure: dipeptides as tyrosine source</article-title>
                  <source>Kidney Int Suppl</source>
                  <year>1989</year>
                  <volume>27</volume>
                  <fpage>s282</fpage>
                  <lpage>s286</lpage>
                  <?supplied-pmid 2517676?>
                  <pub-id pub-id-type="pmid">2517676</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fernstrom</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Fernstrom</surname>
                      <given-names>MH</given-names>
                    </name>
                  </person-group>
                  <article-title>Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain</article-title>
                  <source>J Nutr</source>
                  <year>2007</year>
                  <volume>137</volume>
                  <fpage>1539S</fpage>
                  <lpage>1547S</lpage>
                  <pub-id pub-id-type="doi">10.1093/jn/137.6.1539S</pub-id>
                  <?supplied-pmid 17513421?>
                  <pub-id pub-id-type="pmid">17513421</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Anton</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>Z</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pre-analytical sample quality: metabolite ratios as an intrinsic marker for prolonged room temperature exposure of serum samples</article-title>
                  <source>PLoS One</source>
                  <year>2015</year>
                  <volume>10</volume>
                  <fpage>e0121495</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0121495</pub-id>
                  <?supplied-pmid 25823017?>
                  <pub-id pub-id-type="pmid">25823017</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schutte</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Van den Akker</surname>
                      <given-names>EB</given-names>
                    </name>
                    <name>
                      <surname>Deelen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The effect of standardized food intake on the association between BMI and 1H-NMR metabolites</article-title>
                  <source>Sci Rep</source>
                  <year>2016</year>
                  <volume>6</volume>
                  <fpage>38980</fpage>
                  <lpage>38985</lpage>
                  <pub-id pub-id-type="doi">10.1038/srep38980</pub-id>
                  <?supplied-pmid 27966583?>
                  <pub-id pub-id-type="pmid">27966583</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
